PDE1-IN-5 exhibits anti-inflammatory activity and inhibits LPS-induced expression of iNOS, TNF-α, IL-1α, IL-1β, and IL-6; it demonstrates therapeutic effects in a dextran sulfate sodium (DSS)-induced colitis mouse model of inflammatory bowel disease (IBD); it can be used for IBD research.